Quantcast

Latest Sipuleucel-T Stories

2010-05-10 16:33:00

SEATTLE, May 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.

2010-05-05 10:18:00

SILVER SPRING, Md., May 5 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has approved a new treatment for certain men with advanced prostate cancer. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Called Provenge (sipuleucel-T), the treatment stimulates a patient's own immune system to respond against the cancer. Learn more about FDA's approval of Provenge at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm210620 Sign up for e-mail notices of new FDA...

2010-04-29 16:08:00

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA).

2010-04-29 12:55:00

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S.

2010-04-29 12:08:00

SILVER SPRING, Md., April 29 /PRNewswire-USNewswire/ -- The U.S.

2010-04-21 07:00:00

SEATTLE and WASHINGTON, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced the presentation of additional data from the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) clinical trial showing evidence of immune responses in patients treated with PROVENGE® (sipuleucel-T) and supporting its proposed mechanism of action.

2010-04-19 09:15:27

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

2010-03-03 17:00:00

SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).

2010-02-22 15:00:00

SEATTLE, Feb. 22 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2009. Revenue for the year ended December 31, 2009 was $101,000 compared to $111,000 for year ended December 31, 2008.


Word of the Day
bretelles
  • In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.
The word 'bretelles' comes from a French word meaning 'braces'.